Annals of internal medicine
-
Comment Randomized Controlled Trial Multicenter Study
In ischemic stroke, adding EVT to usual care at 6 to 24 h improved functional status at 90 d.
Olthuis SGH, Pirson FAV, Pinckaers FME, et al; MR CLEAN-LATE investigators. Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial. Lancet. 2023;401:1371-1380. 37003289.
-
Comment Randomized Controlled Trial
In CAD, treat-to-target statins were noninferior to high-intensity statins for a composite clinical outcome.
Hong SJ, Lee YJ, Lee SJ, et al; LODESTAR Investigators. Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial. JAMA. 2023;329:1078-1087. 36877807.
-
Comment Randomized Controlled Trial
In ACS with multivessel CAD, immediate vs. staged complete revascularization was noninferior for a composite outcome at 1 y.
Diletti R, den Dekker WK, Bennett J, et al; BIOVASC Investigators. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial. Lancet. 2023;401:1172-1182. 36889333.
-
Comment Randomized Controlled Trial
In type 2 diabetes, weekly basal insulin Fc was noninferior to daily insulin degludec for HbA1c at 26 wk.
Bue-Valleskey JM, Kazda CM, Ma C, et al. Once-weekly basal insulin Fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: a phase 2 randomized control trial. Diabetes Care. 2023;46:1060-1067. 36944059.
-
Randomized Controlled Trial Multicenter Study
Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2 × 2 Factorial Trial.
An effective and safe treatment for nausea and vomiting of pregnancy (NVP) is lacking. ⋯ The National Key R&D Program of China and the Project of Heilongjiang Province "TouYan" Innovation Team.